Intratio
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-04

APMD vs GERN: stock comparison and AI forecast

Apnimed, Inc. (APMD) and Geron Corp (GERN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Pharmaceutical Preparations

APMD Apnimed, Inc.

Market Cap
$627M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Nasdaq · Pharmaceutical Preparations

GERN Geron Corp

Price
$0.93 -43.6% · 6M
Market Cap
$598M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

APMD · GERN

Key facts

  • APMD and GERN have similar market capitalizations ($627M and $598M).
  • Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricAPMDGERN
Market Cap$627M$598M
P/B Ratio–2.65x
EPS–$-0.13
Book Value/Share–$0.35

Profitability & Margins

MetricAPMDGERN
ROE–-45.6%
Operating Margin–-26.5%
Net Margin–-52.5%
EBT Margin–-34.0%

Financial Health

MetricAPMDGERN
Current Ratio5.19x6.92x
Quick Ratio–5.16x
D/E Ratio–1.53x
Interest Coverage–-2.2x
Working Capital$149M$416M

Cash Flow

MetricAPMDGERN
Operating Cash Flow–-$114M

Income Statement

MetricAPMDGERN
Operating Income–-$52M
Net Income–-$103M
R&D Expense–$72M
SG&A Expense–$155M

Dividend & Shareholder Information

MetricAPMDGERN
Shares Outstanding42M642M
FAQ

APMD vs GERN: stock comparison and AI forecast

Which is bigger, APMD or GERN?

APMD and GERN have similar market capitalizations ($627M and $598M).

Which one does Intratio's AI model rank higher, APMD or GERN?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.